Summary
After furosemide 40 mg i. v. its plasma concentration was significantly higher during an 8-hour period in 6 patients with left sided heart failure than in 8 normal subjects. The plasma clearance was significantly lower in the patients than in the normal subjects — 1.23 and 2.34 ml/kg/min, respectively. The apparently smaller volume of distribution in the cardiac patients (0.140 l/kg and 0.181 l/kg, respectively) was not significantly different. In the group of normal subjects, whose ages ranged from 27 to 74 years, no correlation was found between age and either plasma clearance or volume of distribution. In all the patients, the renal clearance of furosemide rose from the first to the second hour after the injection (average ± SD) — 39±17 and 77±51 ml/min. In normal subjects, the average values did not change — 116±79 and 117±54 ml/min. The urinary excretion of furosemide and a metabolite (probably a glucuronide) was measured in 16 individuals. 24-hour urines from all the subjects investigated contained between 20 and 30 mg unchanged furosemide (average 25.2 mg). In addition, between 2.7 and 11.2 mg (average 6.7 mg) furosemide was excreted as the metabolite in five patients who had been treated with furosemide for at least the preceding 6 months. An average of 0.8±0.8 mg of the metabolite was found in 11 subjects who had not previously been treated with furosemide.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andreasen, F.: Protein binding of drugs in plasma from patients with acute renal failure. Acta pharmacol. toxicol.32, 417–429 (1973)
Andreasen, F., Jakobsen, P.: Determination of furosemide in blood plasma and its binding to proteins in normal plasma and in plasma from patients with acute renal failure. Acta pharmacol. toxicol.35, 49–57 (1974)
Boxenbaum, H.D., Riegelman, S., Eliashoff, R.M.: Statistical estimations in pharmacokinetics. J. Pharmacokinet. Biopharm.2, 123–148 (1974)
Calesnick, B., Christensen, J.A., Richter, M.: Absorption and excretion of furosemide-S35 in human subjects. Proc. Soc. exp. Biol. Med.123, 17–22 (1966)
Davidov, M., Kakaviatos, N., Finnerty, F.A.: Intravenous administration of furosemide in heart failure. J. Amer. med. Ass.200, 824–829 (1967)
Dikshit, K., Vyden, J.K., Forrester, J.S., Chatterjee, K., Prakash, R. and Swan, H.J.C.: Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. New Engl. J. Med.289, 1087–1090 (1973)
Ditlefsen, E.L.: Quinidine concentration in blood and excretion in urine following parenteral administration as related to congestive heart failure. Acta med. scand.159, 105–109 (1957)
Foged, L., Husted, S., Andreasen, F.: Protein binding of phenprocoumon in the absence and presence of furosemide. Acta pharmacol. toxicol.39, 312–320 (1976)
Forrey, A.W., Kimpel, B., Blair, A.D., Cutler, R.E.: Furosemide concentrations in serum and urine, and its binding by serum proteins as measured fluorometrically. Clin. Chem.20, 152–158 (1974)
Gibaldi, M., Nagashima, R., Levy, G.: Relationship between drug concentration in plasma or serum and amount of drug in the body. J. Pharm. Sci.58, 193–197 (1969)
Gibaldi, M., Perrier, D.: Drug elimination and apparent volume of distribution in multicompartment systems. J. Pharm. Sci.61, 952–953 (1972)
Kelly, M.R., Cutler, R.E., Forrey, A.W., Kimpel, B.M.: Pharmacokinetics of orally administered furosemide. Clin. Pharmacol. Ther.15, 178–186 (1974)
Kindt, H., Schmid, E.: Über die Harnausscheidung von Furosemid bei Gesunden und Kranken mit Lebercirrhose. Pharmacol. Clin.2, 221–226 (1970)
Koch-Weser, J., Klein, S. W.: Procainamide dosage schedules, plasma concentrations, and clinical effects. J. Amer. med. Ass.215, 1454–1460 (1971)
Martin, B.K.: Potential effect of the plasma protein on drug distribution. Nature207, 274–276 (1965)
Peltola, P.: Furosemide (Lasix®) as a diuretic. Acta med. scand.177, 777–782 (1965)
Riegelman, S., Loo, J., Rowland, M.: Concept of a volume of distribution and possible errors in evaluation of this parameter. J. Pharm. Sci.57, 128–133 (1968)
Riggs, D.S.: The mathematical approach to physiological problems. pp. 193–217. Baltimore: William and Wilkins 1963
Rupp, W., Zapf, R.M.: Beispiele zur Phase I: Diuretika. Arzneim.-Forsch. (Drug Res.)23, 1665–1668 (1973)
Thomson, P.D., Melmon, K.L., Richardson, J.A., Cohn, K., Steinbrunn, W., Cucihee, R., Rowland, M.: Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann. intern. Med.78, 499–508 (1973)
Vorburger, C.: Die akute Wirkung des Diureticums Fursemid auf das Glomerulumfiltrat, die renale Hämodynamik, die Wasser-, Natrium-, Chlorid- und Kaliumausscheidung und auf den Sauerstoffverbrauch der Nieren. Klin. Wschr.17, 833–839 (1964)
Westlake, W.J.: Problems associated with analysis of pharmacokinetic models. J. Pharm. Sci.60, 882–885 (1971)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Andreasen, F., Mikkelsen, E. Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure. Eur J Clin Pharmacol 12, 15–22 (1977). https://doi.org/10.1007/BF00561400
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561400